Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Jonas, Sangeetha Venugopal, George Yaghmour et al. Nov 03, 2025 pp. 1651-1651 10.1182/blood-2025-1651

Abstract Background: Outcomes for relapsed or refractory (R/R) acute myeloid leukemia (AML) remain poor despite advances in the treatment of...

Efficacy of pirtobrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia: A Bayesian network meta-analysis of randomized controlled trials

Toby Eyre, Lisa M. Hess, Ehsan Masoudi et al. Nov 03, 2025 pp. 5684-5684 10.1182/blood-2025-5684

Abstract Background BRUIN CLL-314 (NCT05254743) is a global phase 3 open-label randomized controlled trial (RCT) comparing pirtobrutinib wit...

Targeting the SDF-1/CXCR4 axis to attenuate pain in sickle cell disease: A preclinical evaluation of AMD3100 as a non-opioid therapeutic strategy

Ammar Alishlash, Simran Malik, Ahmad Lazrak et al. Nov 03, 2025 pp. 4715-4715 10.1182/blood-2025-4715

Abstract Background Sickle cell disease (SCD) is the most common monogenic disorder, affecting about 100,000 Americans a...

RBCs promote VWF tension-dependent activation and hemostatic clot formation under hemodilution: A combined in silico and ex vivo study

Leo Liu, Rukiye Tuna, Binbin Zeng et al. Nov 03, 2025 pp. 3056-3056 10.1182/blood-2025-3056

Abstract Introduction: Dilutional coagulopathy remains a major challenge in trauma and transfusion medicine, yet the mechanistic basis of im...

Comparative efficacy of azacitidine plus venetoclax in patients with de novo and secondary Acute Myeloid Leukemia

Maksim Granatkin, Egor Volchkov, Alina Akhmetova et al. Nov 03, 2025 pp. 5171-5171 10.1182/blood-2025-5171

Abstract Background. Acute myeloid leukemia (AML) comprises a heterogeneous group of hematologic malignancies with a generally poor prognosi...

Shifting first-line paradigms: Real-world treatment outcomes and healthcare burden in non-transplant newly diagnosed multiple myeloma in France (2015-2022)

Feng Lin, Peggy Lin, Giancarlo Pesce et al. Nov 03, 2025 pp. 6353-6353 10.1182/blood-2025-6353

Abstract Introduction: Despite significant advancement in novel agents and combination therapies, multiple myeloma remains incurable. For pa...

Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.

Daniil Katkov, Lourdes Mendez, Nikolai Podoltsev et al. Nov 03, 2025 pp. 7322-7322 10.1182/blood-2025-7322

Abstract Background: Essential thrombocythemia (ET) is a chronic Philadelphia chromosome negative myeloproliferative neoplasm characterized...

Quantifying the impact of vancomycin on short and long term renal function in a contemporary real-world pediatric stem cell transplant cohort

Sophie Odia, Matthew Mason, Valerie Bica et al. Nov 03, 2025 pp. 7728-7728 10.1182/blood-2025-7728

Abstract As survival rates after pediatric hematopoietic cell transplant (HCT) continue to improve, reducing toxicity and maximizing organ f...

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Peter Borchmann, Tom van Meerten, Pierre Bories et al. Nov 03, 2025 pp. 669-669 10.1182/blood-2025-669

Abstract Background: Zamtocabtagene autoleucel (zamto-cel) is an autologous, non-cryopreserved tandem CD20-CD19 directed CAR-T cell therapy...

Obesity is associated with poor prognosis in ph-like acute lymphoblastic leukemia

Maiah Zarrabi, Yueh-Yun Chi, Steven Mittelman et al. Nov 03, 2025 pp. 1542-1542 10.1182/blood-2025-1542

Abstract Philadelphia-like (Ph-like) B-cell Acute Lymphoblastic Leukemia (B-ALL) is a subset of high-risk (HR) ALL, constituting 5-15% of pe...

A case of acute myeloid leukemia with isocitrate dehydrogenase 1 (IDH1) mutation treated with combination therapy, ivosidenib and azacitidine

Shevonne Marcelle, Ambreen Ijaz, Cristina Hamacher Nov 03, 2025 pp. 6920-6920 10.1182/blood-2025-6920

Abstract Background: Acute myeloid leukemia (AML) is the most common leukemia in adults, characterized by clonal prolife...

Utilization and tolerability of R-CHOP and R-mini–CHOP in patients with diffuse large B-cell lymphoma (DLBCL) at a community cancer center

Mumta Essarani, Safwan Muhammad, Shawn Shaikh et al. Nov 03, 2025 pp. 7219-7219 10.1182/blood-2025-7219

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for approximately...

Peripheral blood stem cell collection for patients with multiple myeloma undergoing autologous transplant after quadruplet induction

Oren Pasvolsky, Denai Milton, Mark Tanner et al. Nov 03, 2025 pp. 7557-7557 10.1182/blood-2025-7557

Abstract Background: In recent years, quadruplet induction regimens, including daratumumab, bortezomib, lenalidomide and dexamethasone (D-VR...

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Daniel Bilek, Eva Radova, Veronika Kapustova et al. Nov 03, 2025 pp. 3927-3927 10.1182/blood-2025-3927

Abstract Background: CTCs have emerged as a key prognostic factor in newly diagnosed (ND) MM. However, mechanisms of plasma cell (PC) egressi...

Hemoglobin uptake by liver endothelium prevents von Willebrand factor clearance in sickle cell disease

Marta Wolosowicz, Tomasz Kaminski, Nandhine Rajasekar et al. Nov 03, 2025 pp. 4714-4714 10.1182/blood-2025-4714

Abstract Introduction: Sickle cell disease (SCD) is an autosomal recessive genetic disorder that affects ~100,000 African Americans and over...

Dynamic changes in cytogenetic abnormalities during treatment predict long-term outcomes in multiple myeloma

Jieqiong Zhou, Yuntong Liu, Gang An et al. Nov 03, 2025 pp. 7542-7542 10.1182/blood-2025-7542

Abstract Cytogenetic abnormalities detected by fluorescence in situ hybridization (FISH) at diagnosis are essential for risk stratification...

Thrombophilia testing and thrombotic risk evaluation in beta-thalassemia: A cohort analysis from a hub regional center

Simona Raso, Giulia Maria Camarda, Margherita Vinciguerra et al. Nov 03, 2025 pp. 1143-1143 10.1182/blood-2025-1143

Abstract Background: β-thalassemia (βT) is a group of inherited hemoglobin synthesis disorders, characterized by defecti...

Trends and race-sex disparities in in-hospital mortality of chemotherapy-induced cardiomyopathy in hematologic malignancies

Anushree Venkatesh-Murthy, Adithya Nagendran, Muhammad Yousuf et al. Nov 03, 2025 pp. 4623-4623 10.1182/blood-2025-4623

Abstract Background: Chemotherapy-induced cardiomyopathy (CIC) is a serious, and often irreversible complication in patients treated for hem...

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Thomas Chatzikonstantinou, Persefoni Talimtzi, Eva Minga et al. Nov 03, 2025 pp. 5664-5664 10.1182/blood-2025-5664

Abstract Introduction: Several randomized controlled trials have demonstrated superiority of BTK inhibitors (BTKis) over chemoimmunotherapy...

Endogenous regulation of inflammatory response as a determinant of durable remission without stem cell transplant following brexucabtagene autoleucel (Brexu-cel) therapy in ALL

Sabina Adhikary, Colleen Schweitzer, Daqin Mao et al. Nov 03, 2025 pp. 1588-1588 10.1182/blood-2025-1588

Abstract Introduction: Brexu-cel therapy achieved remarkable overall complete remission rates in the pivotal ZUMA-3 (NCT02614066) for adults...

ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases

Shailaja Hegde, Alexander Khvat, Ruben Karapetian et al. Nov 03, 2025 pp. 1988-1988 10.1182/blood-2025-1988

Abstract Background: The JAK2 V617F mutation is the most frequent recurring mutation noted in all three types of myeloproliferative disorder...

Comparative outcomes of 14,650 patients with mycosis fungoides/Sézary syndrome from academic and community cancer programs

Erin Kaser, Leyla Bojanini, Vanessa Velazquez et al. Nov 03, 2025 pp. 5416-5416 10.1182/blood-2025-5416

Abstract Background: Cutaneous T-cell lymphomas are a group of lymphoproliferative disorders that are characterized by dermal infiltration b...

Real-world outcomes with CAR-T therapy in relapsed/refractory multiple myeloma and severe renal failure: A propensity matched multi-center retrospective Study using trinetx database

Deevyashali Parekh, Sandra Mazzoni, Jason Valent et al. Nov 03, 2025 pp. 4593-4593 10.1182/blood-2025-4593

Abstract Introduction: Two BCMA CAR-T cell therapies ie Idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (...

Serine/glycine starvation induces metabolic rewiring to uncover ATF4-driven therapeutic vulnerabilities in infant ALL

Victoria Assmann, Jonathan Josephs-Spaulding, Lynn McGarry et al. Nov 03, 2025 pp. 5084-5084 10.1182/blood-2025-5084

Abstract Significant progress has been made in treating childhood leukaemia's in recent decades, with a 5-year survival rate of 65%-95%. How...

Impact of fludarabine exposure on overall survival in patients receiving fludarabine/cyclophosphamide reduced intensity conditioning hematopoietic cell transplantation for hematologic malignancies

Biplov Adhikari, Keith Schmidt, Ashley Carpenter et al. Nov 03, 2025 pp. 5979-5979 10.1182/blood-2025-5979

Abstract Allogeneic hematopoietic cell transplantation (alloHCT) is a potentially curative treatment for many hematologic malignancies. Redu...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page